Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-11-12

Clinical Trial Update: Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the topical agent TDM-105795 for androgenetic alopecia in men has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TDM-105795

Snippet

Sponsor: Technoderma Medicines Inc. | Conditions: Alopecia, Androgenetic | Phase 2 | Status: COMPLETED | Results posted: 2025-11-12